Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Life Time Group Holdings Inc. Common Stock (LTH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Life Time Group Holdings Inc. Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Life Time Group Holdings Inc. Common Stock trades at $40.07 (market cap $8.99B). The key difference: Kymera Therapeutics Inc. Common Stock and Life Time Group Holdings Inc. Common Stock are close in size by market cap, and Life Time Group Holdings Inc. Common Stock is more actively traded (3,241,684 versus 1,028,790). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Life Time Group Holdings Inc. Common Stock for 6 Days on average.
| KYMR | LTH | |
|---|---|---|
Market Cap | $8.88B | $8.99B |
Volume | 1,028,790 | 3,241,684 |
Sector | Health | Consumer Cyclical |
52-Week High | $127.31 | $45.73 |
52-Week Low | $55.80 | $24.59 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.27B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Life Time Group Holdings (LTH) trades at $39.66, down 1.76% today, amid bullish technical signals and strong fundamental performance. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.48 exceeding expectations by 28%. Recent expansion news includes new athletic clubs in Florida and Boston, highlighting growth initiatives. Analyst consensus remains strongly bullish with an 86.7% buy rating and $55.17 price target, implying 39% upside.
LTH presents a compelling growth story with expanding facilities and robust profitability margins. Key risks include execution of expansion plans and consumer discretionary spending sensitivity. The valuation at 21.7x P/E appears reasonable given 13% net margins and double-digit ROE. Near-term catalyst is Q3 2026 earnings on October 29, 2026, which could validate the bullish analyst outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Life Time Group Holdings Inc. Common Stock
Life Time operates fitness and lifestyle centers that offer gyms, classes, sports facilities, and wellness services.
Read more on LTH →
